Scarica l'app Stockscreener
27.33
4.48%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$26.25
Aprire:
$26.59
Volume 24 ore:
3.57M
Relative Volume:
0.36
Capitalizzazione di mercato:
$10.65B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.1306
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-1.77%
1M Prestazione:
+14.85%
6M Prestazione:
+4.52%
1 anno Prestazione:
-52.14%
Intervallo 1D:
$26.38
$27.74
Intervallo di 1 settimana:
$26.01
$28.30
Portata 52W:
$23.15
$58.45
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.37 | 10.21B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.83 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
483.23 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.94 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
810.77 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
319.12 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Leerink Partners Adjusts Price Target on Moderna to $16 From $15, Maintains Underperform Rating - MarketScreener
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Moderna: Q3 Earnings PreviewI Fear A Halloween Horror Show (Downgrade) (NASDAQ:MRNA) - Seeking Alpha
Lobbying Update: $80,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks - GuruFocus
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Norwich Bulletin
How to use Fibonacci retracement on Moderna Inc.July 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Key facts: Moderna faces cash flow challenges; stock rises on therapy data - TradingView
Moderna (MRNA) Stock Trades Up, Here Is Why - The Globe and Mail
Moderna’s Off-The-Shelf Cancer Immunotherapy Shows Early Promise - insights.citeline.com
Is Moderna Inc. meeting your algorithmic filter criteriaRate Hike & Fast Exit Strategy with Risk Control - newser.com
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Benzinga
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment - GuruFocus
What’s next for Moderna Inc. stock priceJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Moderna (MRNA) Tops Healthcare Short Interest Rankings - GuruFocus
Intraday pattern recognizer results for Moderna Inc.2025 Volume Leaders & AI Driven Stock Movement Reports - newser.com
Respiratory Syncytial Virus (RSV) Market Explosion To hit - openPR.com
Moderna Claims Early Victory for Cancer Antigen in Melanoma - BioSpace
Moderna, Inc. (MRNA) Stock Analysis: Navigating Volatility With A 65% Potential Upside - DirectorsTalk Interviews
Moderna reports early cancer therapy data at medical conference - StreetInsider
KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC - MarketBeat
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress - Times Herald
Moderna says it presents promising early data for investigational cancer antigen therapy - MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Shreveport Times
Moderna (NASDAQ:MRNA) Given New $32.00 Price Target at Morgan Stanley - MarketBeat
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView
MRNA: Morgan Stanley Raises Price Target for Moderna | MRNA Stock News - GuruFocus
Covid-19 Vaccine Recommendations | Moderna - OurQuadCities
Moderna assists with the evolving landscape of COVID-19 vaccine - KHGI
AstraZeneca ups investment in Virginia; Moderna vets launch VC fund - BioPharma Dive
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Newport Daily News
Should Moderna's (MRNA) Improved Revenue Trends Prompt New Action From Investors? - Yahoo Finance
Is Moderna Inc. trending in predictive chart modelsRate Hike & Daily Stock Trend Reports - newser.com
Moderna, Inc. $MRNA Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Best Biotech Stocks To Follow NowOctober 6th - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
GSK Doesn't Have To Explain COVID Vax Claims For Moderna - Law360
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Updated COVID shot led to less severe illness, fewer hospitalizations last year, US study finds - MarketScreener
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further? - ts2.tech
Moderna, Inc. (MRNA): Among the Best Vaccine Stocks to Buy According to Hedge Funds - MSN
Moderna (MRNA) COVID-19 Booster Recommendations Updated by CDC - GuruFocus
CDC adopts individual-based decision-making for COVID-19 shots (MRNA:NASDAQ) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna - WCIV
Moderna (MRNA): Assessing Valuation After Recent 12% Share Price Jump and Updated Financials - Yahoo Finance
Will Moderna Inc. see short term momentum2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Key metrics from Moderna Inc.’s quarterly data2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 16% Return (vs. -31% YTD) [10/3/2025] - Trefis
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):